Key points are not available for this paper at this time.
Population
Patients with peripheral artery disease
Comparison
Vorapaxar by intensity of background lipid-lowering therapy
Design
Post hoc or subgroup analysis of a randomized trial
Answers are grounded in this paper and cite their sources.
Supports dual lipid-thrombotic targeting to optimize PAD outcomes; confirms vorapaxar efficacy independent of statin background.
-interaction=0.715 and 0.073, respectively). Event rates were lowest in patients receiving the combination of statin therapy and vorapaxar. Conclusions In conclusion, statin use and intensity is associated with significantly lower rates of MACEs and limb ischemic events. Thrombin inhibition with vorapaxar is effective regardless of background statin therapy. These results suggest that targeting both lipid and thrombotic risk in peripheral artery disease is necessary in order to optimize outcomes.
No takes yet. Share an insight, caveat, or question.
Gilchrist et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: